Covagen enters into a strategic research collaboration and license agreement with Mitsubishi Tanabe for the development of bispecific FynomAbs. Brennan CaruthersOctober 17, 2012
Genocea Closes $30 Million in Series C Financing. The Bill & Melinda Gates Foundation and CVF join as new investors. Brennan CaruthersOctober 10, 2012
Genocea Initiates a Phase 1/2a Study with its Therapeutic Vaccine Candidate for Herpes Simplex Virus-2 (HSV-2). Brennan CaruthersAugust 15, 2012
Pronota's Risk Stratification Test Breaks New Ground in the Early Detection of Pre-term Pre-eclampsia. Brennan CaruthersJuly 9, 2012
Genkyotex Announces Successful Phase Ia Data with First in Class NOX Inhibitor GKT137831. Brennan CaruthersJune 22, 2012
Pronota Strengthens Management Team Former VP Corporate Development Genzyme joins as CBO. Brennan CaruthersMarch 16, 2012
Shire to acquire FerroKin BioSciences, Inc., and its Phase 2 iron chelator treatment. Brennan CaruthersMarch 15, 2012
Pronota announces EUR 3.7 million Series C financing ; management and board changes. Brennan CaruthersJanuary 20, 2012
Syndexa Pharmaceuticals Expands Series B1 Financing Round with Investment by MP Healthcare Venture Management, Inc. Brennan CaruthersDecember 30, 2011
GenKyoTex Starts Phase 1 Trial with First in Class NOX inhibitor GKT137831. Dual NOX1/4 Inhibitor Targets Treatment of Diabetic Nephropathy. Brennan CaruthersOctober 31, 2011
F-Star and Merck Serono to Collaborate in the Discovery and Development of Novel Targeted Biologics. Brennan CaruthersSeptember 7, 2011
GenKyoTex raises CHF 18 million in a Series C Venture Financing to develop NOX enzyme inhibitors. Brennan CaruthersMay 24, 2011
Pronota and Molecuence announce collaboration in protein biomarker discovery. Brennan CaruthersFebruary 22, 2011
